Holding option open for subsequent treatment. Beginning therapy with a protease inhibitor
MMW Fortschritte der Medizin 142(3 Suppl): 8-9
2000
ISSN/ISBN: 1438-3276 PMID: 10893948 Document Number: 516292
Document emailed within 1 workday
Related Documents
Ritt, M.J.; Hillebrand-Haverkort, M.E.; ten Veen, J.H. 2001: Local treatment of facial lipodystrophy in patients receiving HIV protease inhibitor therapy Acta Chirurgiae Plasticae 43(2): 54-56Hammer, S.M.; Vaida, F.; Bennett, K.K.; Holohan, M.K.; Sheiner, L.; Eron, J.J.; Wheat, L.Joseph.; Mitsuyasu, R.T.; Gulick, R.M.; Valentine, F.T.; Aberg, J.A.; Rogers, M.D.; Karol, C.N.; Saah, A.J.; Lewis, R.H.; Bessen, L.J.; Brosgart, C.; DeGruttola, V.; Mellors, J.W. 2002: Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial JAMA 288(2): 169-180
Gaillard, M.C.; Reichberg, S.B.; Nogueira, C.M.; Kilroe-Smith, T.A. 1993: Differences in elastase-binding activity of alpha 1-protease inhibitor and alpha 2-macroglobulin for asthma patients and control subjects with various alpha 1-protease inhibitor phenotypes Clinical Chemistry 39(4): 675-679
Sherman, K.E.; Shire, N.J.; Cernohous, P.; Rouster, S.D.; Omachi, J.H.; Brun, S.; Da Silva, B. 2005: Liver injury and changes in hepatitis C virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients : Lopinavir-ritonavir versus nelfinavir Clinical Infectious Diseases 41(8): 1186-1195
Della Porta, P.; Soeltl, R.; Krell, H.W.; Collins, K.; O'Donoghue, M.; Schmitt, M.; Krüger, A. 1999: Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo Anticancer Research 19(5b): 3809-3816
Besson, C.; Jubault, V.; Viard, J.P.; Pialoux, G. 1998: Ketoacidosis associated with protease inhibitor therapy Aids 12(11): 1399-1400
Cabot de Vega, E.; Fontecha Gómez, B.J.; Solé Arnau, R.; Pedrol Clotet, E. 1999: Peripheral lipodystrophy associated with protease inhibitor therapy Revista Clinica Espanola 199(8): 546-547
2002: Sartan as a new therapy option. When heart failure patients cannot tolerate an ACE inhibitor MMW Fortschritte der Medizin 144(40): 49
Cupisti, A.; Brunori, G.; Di Iorio, B.Raffaele.; D'Alessandro, C.; Pasticci, F.; Cosola, C.; Bellizzi, V.; Bolasco, P.; Capitanini, A.; Fantuzzi, A.Laura.; Gennari, A.; Piccoli, G.Barbara.; Quintaliani, G.; Salomone, M.; Sandrini, M.; Santoro, D.; Babini, P.; Fiaccadori, E.; Gambaro, G.; Garibotto, G.; Gregorini, M.; Mandreoli, M.; Minutolo, R.; Cancarini, G.; Conte, G.; Locatelli, F.; Gesualdo, L. 2018: Nutritional diet therapy in the management of the patient with Chronic Kidney Disease in advanced phase to delay the beginning and reduce the frequency of dialysis. An option also in the pre-emptive transplant program Giornale Italiano di Nefrologia: Organo Ufficiale Della Societa Italiana di Nefrologia 35(5)
2000: Ritonavir/Saqinavir: dual protease inhibitor combination. Salvage therapy MMW Fortschritte der Medizin 142(3 Suppl): 41
Sangraula, H.; Sharma, K.K.; Dwivedi, S. 2001: Antiretroviral protease inhibitor therapy leads to hyperglycaemia, hyperlipidaemia and lipodystrophy National Medical Journal of India 14(6): 347-348
Buch, H.J. 1970: Treatment of arthrosis with protease-inhibitor Contrykal Das Deutsche Gesundheitswesen 25(20): 947-950
Bard, J-Marie.; Lassalle, Régis.; Capeau, J.; Bach-Ngohou, K.; Nazih-Sanderson, Fçoise.; Rémy, Gérard.; Reynes, J.; Ecobichon, J-Luc.; Savès, M.; Raffi, Fçois. 2006: Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy Antiviral Therapy 11(3): 361-370
Uchishiba, M.A.; Colley, C.; Strausbaugh, L.; Ward, T. 1997: Can ongoing education by a clinical pharmacist decrease the mean viral burden for patients on protease inhibitor therapy? Pharmacotherapy 17(5): 1122
Galegov, G.A. 2007: Protease inhibitor Kaletra (Lopinavir/Ritonavir): significance and role in antiretroviral therapy of HIV infection and AIDS Antibiotiki i Khimioterapiia 52(1-2): 42-45
Nigro, L.; Romano, F.; Tosto, S.; Zagami, A.; Bruno, S.; Nunnari, A. 1999: Severe hepatitis in a HIV-positive subject under treatment with protease inhibitor Italian Journal of Gastroenterology and Hepatology 31(1): 85-86
Traber, D.L.; Adams, T.; Sziebert, L.; Williams, P.; Traber, L.D. 1984: Failure of a protease inhibitor to affect the cardiopulmonary response to endotoxin when combined with a cyclooxygenase inhibitor Circulatory Shock 13(4): 319-323
Novelli, G.P.; Innocenti, P.; Livi, P. 1993: Gabexate mesilate (FOY), a new synthetic protease inhibitor, in the treatment of shock. An Italian multicenter study Minerva Anestesiologica 59(5): 247-253
Taylor, B.S.; Hunt, G.; Abrams, E.J.; Coovadia, A.; Meyers, T.; Sherman, G.; Strehlau, R.; Morris, L.; Kuhn, L. 2011: Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa AIDS research and human retroviruses 27(9): 945-956
Luber, A.D. 2005: Use of acid-reducing agents in protease inhibitor-based HAART and the potential for negative treatment outcomes Aids Reader 15(12): 692